Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACHN
Previous Symbol
CUSIP00448Q20
Phone203-624-7000
Debt
Debt-to-Equity RatioN/A
Current Ratio33.23
Quick Ratio33.23
Price-To-Earnings
Trailing P/E Ratio-4.66
Forward P/E Ratio-5.56
P/E GrowthN/A
Sales & Book Value
Annual Sales$15 million
Price / Sales26.71
Cash FlowN/A
Price / CashN/A
Book Value$2.35 per share
Price / Book1.23
Profitability
EPS (Most Recent Fiscal Year)($0.62)
Net Income$-85,230,000.00
Net MarginsN/A
Return on Equity-25.48%
Return on Assets-24.70%
Miscellaneous
Employees88
Outstanding Shares138,620,000
Market Cap$399.21 million
OptionableOptionable
Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions
What is Achillion Pharmaceuticals' stock symbol?
Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."
How were Achillion Pharmaceuticals' earnings last quarter?
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) posted its quarterly earnings data on Wednesday, November, 7th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. View Achillion Pharmaceuticals' Earnings History.
When is Achillion Pharmaceuticals' next earnings date?
What price target have analysts set for ACHN?
3 brokerages have issued 1 year target prices for Achillion Pharmaceuticals' shares. Their forecasts range from $3.50 to $5.00. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 55.7% from the stock's current price. View Analyst Price Targets for Achillion Pharmaceuticals.
What is the consensus analysts' recommendation for Achillion Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals.
Has Achillion Pharmaceuticals been receiving favorable news coverage?
News coverage about ACHN stock has trended neutral on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of 0.1 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Achillion Pharmaceuticals' key competitors?
Some companies that are related to Achillion Pharmaceuticals include Cambrex (CBM), Enanta Pharmaceuticals (ENTA), G1 Therapeutics (GTHX), Corcept Therapeutics (CORT), The Medicines (MDCO), Theravance Biopharma (TBPH), Spectrum Pharmaceuticals (SPPI), Phibro Animal Health (PAHC), Biohaven Pharmaceutical (BHVN), Nabriva Therapeutics (NBRV), Insmed (INSM), Mirati Therapeutics (MRTX), Myovant Sciences (MYOV), Portola Pharmaceuticals (PTLA) and Tricida (TCDA).
Who are Achillion Pharmaceuticals' key executives?
Achillion Pharmaceuticals' management team includes the folowing people:
- Mr. Joseph Truitt, Pres, CEO & Director (Age 53)
- Ms. Mary Kay Fenton, Exec. VP, CFO & Treasurer (Age 54)
- Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 63)
- Mr. Paul Firuta, Exec. VP & COO (Age 52)
- Mr. Brian R. DiDonato, VP of Investor Relations & Corp. Communications (Age 51)
Who are Achillion Pharmaceuticals' major shareholders?
Achillion Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.60%), Dimensional Fund Advisors LP (5.18%), Point72 Asset Management L.P. (1.30%), Teachers Advisors LLC (1.27%), Baker BROS. Advisors LP (1.18%) and Nexthera Capital LP (1.14%). Company insiders that own Achillion Pharmaceuticals stock include & Johnson Johnson, Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Institutional Ownership Trends for Achillion Pharmaceuticals.
Which major investors are selling Achillion Pharmaceuticals stock?
ACHN stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Renaissance Technologies LLC, TIAA CREF Investment Management LLC, Baker BROS. Advisors LP, Panagora Asset Management Inc., Tekla Capital Management LLC, Virtus ETF Advisers LLC and Credit Suisse AG. View Insider Buying and Selling for Achillion Pharmaceuticals.
Which major investors are buying Achillion Pharmaceuticals stock?
ACHN stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Nexthera Capital LP, Assenagon Asset Management S.A., Opus Point Partners Management LLC, Dimensional Fund Advisors LP, Opaleye Management Inc., JPMorgan Chase & Co. and JPMorgan Chase & Co.. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Insider Buying and Selling for Achillion Pharmaceuticals.
How do I buy shares of Achillion Pharmaceuticals?
Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achillion Pharmaceuticals' stock price today?
One share of ACHN stock can currently be purchased for approximately $2.89.
How big of a company is Achillion Pharmaceuticals?
Achillion Pharmaceuticals has a market capitalization of $399.21 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-85,230,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Achillion Pharmaceuticals employs 88 workers across the globe.
What is Achillion Pharmaceuticals' official website?
How can I contact Achillion Pharmaceuticals?
Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.
MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
